Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPAR: Total Neoadjuvant Chemotherapy in Ovarian Cancer
NCT06980545Phase 3Not yet recruiting
- Sponsor
- Assiut University
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised trial of paclitaxel and carboplatin in ovarian cancer (2 arms), sponsored by Assiut University. Primary endpoints: Event Free Survival at 50 months, Safety and Tolerability and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06980545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980545.